Clinical Trials on Acute Myeloid Leukemia, Refractory in New Zealand

Total 1166 results

Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
Aptose Biosciences Inc.

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE)

Relapsed or Refractory Acute Myeloid Leukemia

United States, Germany, Spain, Korea, Republic of, Australia, New Zealand
Yale University
Vanderbilt University

Completed

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Relapsed/Refractory Acute Myeloid Leukemia

United States
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
National Cancer Institute (NCI)

Completed

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Leukemia Cutis | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL

United States
Cellectis S.A.

Recruiting

Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMELI-01)

Relapsed/Refractory Acute Myeloid Leukemia

United States
Cornerstone Pharmaceuticals

Terminated

Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML

Relapsed/Refractory Acute Myeloid Leukemia

United States, Spain, Korea, Republic of, France, Australia, Belgium, Austria, Germany, Poland
Amgen

Active, not recruiting

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

Relapsed or Refractory Multiple Myeloma | Relapsed or Refractory Acute Myeloid Leukemia

United States, Australia, Japan, Germany, Canada
Roswell Park Cancer Institute
Pfizer

Active, not recruiting

Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States, Canada
Caribou Biosciences, Inc.

Recruiting

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AMpLify)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
Amgen

Terminated

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States, Korea, Republic of, Australia, Japan, Germany, Canada
University of Birmingham
Assistance Publique - Hôpitaux de Paris; Pfizer; Cancer Research UK; National Cancer...

Recruiting

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01)

Acute Myeloid Leukaemia

France, Switzerland, United Kingdom, New Zealand, Australia, Ireland
University of Sydney
Melbourne Health; Royal Brisbane and Women's Hospital

Unknown

Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation (SCRAMBLE)

Acute Myeloid Leukaemia

Australia
Kronos Bio

Terminated

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States, Spain
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Acute Myeloid Leukaemia

France, United States, Australia
National Cancer Institute (NCI)

Active, not recruiting

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
St. Jude Children's Research Hospital
AbbVie; Gateway for Cancer Research; Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous Lineage

United States
Children's Oncology Group

Recruiting

A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage | Recurrent Acute Myeloid Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Suspended

Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
GlaxoSmithKline

Terminated

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, Australia, Canada
Sanofi

Terminated

A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukaemia

United States
Arog Pharmaceuticals, Inc.

Recruiting

Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

United States, Germany, Spain, Italy, France, Canada
National Cancer Institute (NCI)

Active, not recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
Roswell Park Cancer Institute

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Alkylating Agent-Related Acute Myeloid Leukemia | Refractory Anemia With Excess Blasts in Transformation

United States
Massachusetts General Hospital
Patient-Centered Outcomes Research Institute

Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia (SCOPE-L)

High Risk Acute Myeloid Leukemia | Relapsed Adult AML | Primary Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Refractory Anemia | Myelodysplastic Syndrome With Ring Sideroblasts

United States
Skyline Diagnostics BV
Illumina, Inc.

Terminated

Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler

Acute Myeloid Leukemia (AML) | Acute Promyelocytic Leukemia (APL) | Refractory Anemia With Excess of Blasts (RAEB)

United States, Germany, Netherlands, United Kingdom
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Antisoma Research

Terminated

A Study of AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Taiwan, Australia, New Zealand
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

Relapsed or Refractory Acute Myeloid Leukemia | Relapsed or Refractory Chronic Myelomonocytic Leukemia

United States, Israel, Spain
Syndax Pharmaceuticals

Active, not recruiting

A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Undifferentiated Leukemia | Relapsed/Refractory Leukemias | Mixed Phenotype Acute Leukemia

United States, Canada
Foghorn Therapeutics Inc.

Recruiting

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Relapsed Acute Myeloid Leukemia | Relapsed Myelodysplastic Syndromes | Refractory Myelodysplastic Syndromes | Advanced Hematologic Malignancy | Relapsed Chronic Myelomonocytic Leukemia

United States
Roswell Park Cancer Institute
Celgene

Withdrawn

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level

United States
National Cancer Institute (NCI)
Children's Oncology Group

Completed

Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome

United States
Race Oncology Ltd
Astex Pharmaceuticals, Inc.

Withdrawn

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS (BISECT)

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Higher Risk Myelodysplastic Syndrome

Australia
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Myeloproliferative Neoplasm | Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
Vastra Gotaland Region
Australasian Leukaemia and Lymphoma Group; The Canadian Blood and Marrow Transplant...

Completed

Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia

Acute Myeloid Leukemia

Finland, Australia, Canada, New Zealand, Sweden, Estonia, Germany, Greece, Norway
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
Kura Oncology, Inc.

Recruiting

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Myeloid Sarcoma | Acute Myeloid Leukemia Recurrent | Mixed Phenotype Acute Leukemia | Mixed Lineage Acute Leukemia | Refractory AML | NPM1 Mutation | Mixed Lineage Leukemia Gene Mutation | AML With Mutated NPM1 | KMT2Ar

United States
National Cancer Institute (NCI)

Completed

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic Syndrome | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia... and other conditions

United States
Opna-IO LLC

Completed

A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

High-risk Myelodysplastic Syndrome (MDS) | Relapsed Acute Myeloid Leukemia (AML) | Refractory Acute Myeloid Leukemia (AML)

United States
Cullinan Oncology Inc.

Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome (MDS) | Relapsed/Refractory Acute Myeloid Leukemia (AML)

United States
Remix Therapeutics

Recruiting

Study of REM-422 in Patients With AML or Higher Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Myeloid Leukemia Refractory | Higher Risk Myelodysplastic Syndromes

United States
Antisoma Research

Completed

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

Leukemia, Myeloid

United States, New Zealand
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Roswell Park Cancer Institute
Celldex Therapeutics

Completed

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Refractory Anemia | Blasts 30 Percent or Less of Bone Marrow Nucleated Cells

United States

Clinical Trials on Acute Myeloid Leukemia, Refractory in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations